HIV Single-Pill BIC/LEN Matches Complex Regimens in Oldest-Ever Registration Trial
The average person enrolled in the ARTISTRY-1 clinical trial had been living with HIV for 28 years. Many were taking up to eleven pills daily to keep their virus suppressed - a regimen reflecting decades of accumulated drug resistance, clinical compromises, and the evolution of HIV treatment across generations of medication. For this population, the question was whether a single daily tablet could do what a handful of pills was doing.
The phase 3 trial data, published in The Lancet and presented simultaneously at CROI 2026, suggest the answer is yes. The combination tablet containing bictegravir and lenacapavir (BIC/LEN) maintained HIV viral suppression - levels below 50 copies per milliliter - in nearly 96% of participants who switched from complex multi-pill treatments. The result matched the outcomes of participants who continued their existing regimens.
Trial Design and Patient Profile
The ARTISTRY-1 trial enrolled more than 550 people living with HIV across 15 countries. Participant ages ranged from 22 to 84, with a median of 60 - considerably older than the typical HIV medication trial population. Most participants were taking between two and eleven pills per day for their HIV care, with approximately 40% requiring antiretrovirals more than once daily.
Most trial participants had resistance to prior HIV therapies - meaning the simplest one-pill-once-daily regimens were not suitable options for them. Many also carried additional chronic conditions: cardiovascular disease, kidney disease, and other age-related diagnoses that create drug interaction risks when combined with multi-drug HIV regimens.
Efficacy, Safety, and Lipid Improvements
On the primary efficacy measure - proportion maintaining viral suppression - participants who switched to BIC/LEN performed comparably to those who continued existing therapy, with suppression rates around 94-96% in both groups. No new drug resistance emerged among those who switched.
Participants switching to BIC/LEN experienced improvements in lipid profiles, with most reporting fewer lipid-related side effects such as elevated cholesterol. For a population already at elevated cardiovascular risk due to age and long-term antiretroviral therapy, this represents a clinically meaningful secondary benefit. No significant or novel safety concerns were identified.
Bictegravir and Lenacapavir: Two Mechanisms in One Tablet
Bictegravir is an integrase strand transfer inhibitor - one of the most commonly used drug classes in modern HIV treatment. Lenacapavir targets the HIV capsid protein through a different mechanism, belonging to a class not previously used in standard oral daily therapy. The combination of two mechanistically distinct drugs with activity against resistant viral strains is what makes BIC/LEN potentially viable for patients whom simpler combinations cannot reach.
Additional trials are underway to address questions about very long-term durability and rare adverse events that require larger populations to detect. For the population in ARTISTRY-1 - long-term survivors managing HIV alongside aging, multiple comorbidities, and decades of treatment complexity - the trial results offer a meaningful simplification option that was not previously available with evidence to support it.